Faculty of Kinesiology & Recreation Management, University of Manitoba, Winnipeg, Manitoba, Canada; Institute of Cardiovascular Sciences, St. Boniface Hospital Albrechtsen Research Centre, Winnipeg, Manitoba, Canada; Max Rady College of Medicine, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, Manitoba, Canada.
Faculty of Kinesiology & Recreation Management, University of Manitoba, Winnipeg, Manitoba, Canada; Institute of Cardiovascular Sciences, St. Boniface Hospital Albrechtsen Research Centre, Winnipeg, Manitoba, Canada.
Exp Gerontol. 2020 May;133:110859. doi: 10.1016/j.exger.2020.110859. Epub 2020 Feb 1.
Frailty is a risk factor for cardiovascular disease (CVD). Biomarkers have the potential to detect the early stages of frailty, such as pre-frailty. Myokines may act as biomarkers of frailty-related disease progression, as a decline in muscle health is a hallmark of the frailty phenotype. This study is a secondary analysis of 104 females 55 years of age or older with no previous history of CVD. Differences in systemic myokine concentrations based on frailty status and CVD risk profile were examined using a case-control design. Propensity matching identified two sets of 26 pairs with pre-frailty as the exposure variable in low or elevated CVD risk groups for a total 104 female participants. Frailty was assessed using the Fried Criteria (FC) and CVD risk was assessed using the Framingham Risk Score (FRS). Factorial ANOVA compared the main effects of frailty, CVD risk, and their interaction on the concentrations of 15 myokines. Differences were found when comparing elevated CVD risk status with low for the concentrations of EPO (384.76 ± 1046.07 vs. 206.63 ± 284.61 pg/mL, p = .001), FABP3 (2772.61 ± 3297.86 vs. 1693.31 ± 1019.34 pg/mL, p = .017), FGF21 (193.17 ± 521.09 vs. 70.18 ± 139.51 pg/mL, p = .010), IL-6 (1.73 ± 4.97 vs. 0.52 ± 0.89 pg/mL, p = .023), and IL-15 (2.62 ± 10.56 vs. 0.92 ± 1.25 pg/mL, p = .022). Pre-frail females had lower concentrations of fractalkine compared to robust (27.04 ± 20.60 vs. 103.62 ± 315.45 pg/mL, p = .004). Interaction effects between frailty status and CVD risk for FGF21 and OSM were identified. In elevated CVD risk, pre-frail females, concentrations of FGF21 and OSM were lower than that of elevated CVD risk, robust females (69.10 ± 62.86 vs. 317.24 ± 719.69, p = .011; 1.73 ± 2.32 vs. 24.43 ± 69.21, p = .018, respectively). These data identified specific biomarkers of CVD risk and biomarkers of frailty that are exacerbated with CVD risk.
虚弱是心血管疾病（CVD）的一个风险因素。生物标志物有可能检测到虚弱的早期阶段，如前虚弱。肌因子可能作为与虚弱相关的疾病进展的生物标志物，因为肌肉健康的下降是虚弱表型的一个标志。这项研究是对 104 名年龄在 55 岁或以上且无心血管疾病既往史的女性进行的二次分析。使用病例对照设计，根据虚弱状况和 CVD 风险状况，检查了系统肌因子浓度的差异。倾向匹配确定了两组 26 对，在低或高 CVD 风险组中，将前虚弱作为暴露变量，总共有 104 名女性参与者。使用 Fried 标准（FC）评估虚弱，使用 Framingham 风险评分（FRS）评估 CVD 风险。因子方差分析比较了虚弱、CVD 风险及其对 15 种肌因子浓度的交互作用的主要影响。与低 CVD 风险状态相比，高 CVD 风险状态时发现了差异，EPO（384.76±1046.07 与 206.63±284.61 pg/mL，p=0.001）、FABP3（2772.61±3297.86 与 1693.31±1019.34 pg/mL，p=0.017）、FGF21（193.17±521.09 与 70.18±139.51 pg/mL，p=0.010）、IL-6（1.73±4.97 与 0.52±0.89 pg/mL，p=0.023）和 IL-15（2.62±10.56 与 0.92±1.25 pg/mL，p=0.022）的浓度较高。与强壮女性相比，前虚弱女性的 fractalkine 浓度较低（27.04±20.60 与 103.62±315.45 pg/mL，p=0.004）。还确定了 FGF21 和 OSM 之间虚弱状态和 CVD 风险之间的相互作用效应。在高 CVD 风险中，前虚弱女性的 FGF21 和 OSM 浓度低于高 CVD 风险、强壮女性的浓度（69.10±62.86 与 317.24±719.69，p=0.011；1.73±2.32 与 24.43±69.21，p=0.018，分别）。这些数据确定了特定的 CVD 风险生物标志物和与 CVD 风险加剧的虚弱生物标志物。
